← Back to Clinical Trials
Recruiting NCT07166068

NCT07166068 The Effect of Mobilization on Inflammatory Biomarkers in Patients With Knee Osteoarthritis.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07166068
Status Recruiting
Phase
Sponsor University of Jazan
Condition Knee Osteoarthritis
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2025-09-20
Primary Completion 2026-02-20

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Manual Therapy (Mobilization with Movement)Exercisesham mobilization

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2025-09-20 with a primary completion date of 2026-02-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is designed to investigate whether a hands-on therapy called Mobilization with Movement (MWM) can reduce pain and inflammation in individuals with knee osteoarthritis (OA). The investigators will compare MWM to a sham treatment that resembles mobilization but does not involve the specific therapeutic movements. Both groups will also receive standard care, including exercise and education about managing knee OA. A total of 40 adults (aged 18 years and older) with moderate to severe knee OA will be enrolled. Participants will be randomly assigned to either the MWM group or the sham group. Each intervention will be delivered twice per week over a four-week period. Outcomes will include measures of inflammation obtained from blood samples, self-reported pain levels, and assessments of knee function before and after the intervention period. It is hypothesized that individuals allocated to the MWM group will demonstrate reduced inflammation and pain compared with those in the sham group. The findings of this study may help clarify the potential role of MWM as a treatment option for knee OA.

Eligibility Criteria

Inclusion Criteria: * Clinical diagnosis of unilateral or bilateral knee osteoarthritis (OA) according to the criteria of the American College of Rheumatology * Age ≥ 18 years * Kellgren-Lawrence grade 2 or 3 knee OA * Pain intensity \> 3 on a visual analogue scale (VAS) * Body mass index (BMI) between 18.5 and 30 kg/m² Exclusion Criteria: * Knee or lower limb surgery within the last six months. * Significant joint disorders (e.g., rheumatoid arthritis, gout, or other inflammatory arthritis). * Recent significant acute infections. * Contraindications to mobilization with movement. * Current or recent use systemic glucocorticoids, intra-articular glucocorticoid injections or intra-articular hyaluronic acid injections.

Contact & Investigator

Central Contact

Abdulraouf Ayoub, PT

✉ aayoub@jazanu.edu.sa

📞 +966500057742

Frequently Asked Questions

Who can join the NCT07166068 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Knee Osteoarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07166068 currently recruiting?

Yes, NCT07166068 is actively recruiting participants. Contact the research team at aayoub@jazanu.edu.sa for enrollment information.

Where is the NCT07166068 trial being conducted?

This trial is being conducted at Jizan, Saudi Arabia.

Who is sponsoring the NCT07166068 clinical trial?

NCT07166068 is sponsored by University of Jazan. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology